Sakura enables optimal only advanced staining results
Imagine a new quality standard that improves the lives of patients and lab professionals in cancer care.
Pathologists know that a fast and accurate diagnosis is crucial for the patient journey. When the diverging roads of treatment lie ahead – one path leading to recovery and the other the opposite – it’s the pathologist who must point the way. But with no quality standard for the result, it has always been difficult for pathologists to give those vital directions with confidence.
Quality has been key in staining and immunohistochemistry (IHC) for decades, but everything from less-optimal antibodies to insufficient dilutions has meant that one in three slides isn’t accurate enough for a correct diagnosis. Add an abundance of variables to the mix and you get the current status quo – a situation that affects patients in more ways than we have ever imagined.
The vast majority of unsuitable slides result from weak staining that results in false negatives; the remainder is caused by poor signal-to-noise ratio that generates false positives. And yet, policies and procedures for staining are largely decided on a lab-by-lab basis. This failure results from delayed standardisation, which makes suboptimal lab performance all the more likely.
Advanced staining: Is it an art or a science?
The world of advanced staining is often a complicated, delayed, and inaccurate place. It’s been this way for so long that to many, it may not even register as a problem, but it is likely making everyone’s work harder than it needs to be. We have been questioning this status quo – and we think it’s time for change.
We question the situation this which tissue diagnostics finds itself. Better yet, we are offering a solution – one that could see tissue diagnostics become the fast, accurate, and trustworthy process it needs to be. With a growing interest in digital pathology, there is an equally growing need for IHC standardisation and optimisation, but we have decades’ worth of catching up to do. Likewise, recent IVDR regulation in the EU means that compliance is required now, not at some distant future point.
To help labs catch up, we have been working hard creating long-term, sustainable solutions with our mission: Advancing cancer diagnoses by providing integrated solutions for anatomic pathology and patients. We’ve been improving the lab’s workflow, standardising and automating processes in pre-analytics already with our closed systems: the xylene-free continuous rapid tissue processor and the automated tissue embedder. From autumn, we extended our support, and now we provide standardised, closed-loop technology also in IHC. Our new Advanced Staining System uses single protocols for over 130 optimal antibodies, offering the convenience of reduced IHC assay calibration and validation. We combine this with third-party quality control and by only offering optimal scoring antibodies – giving reassurance to pathologists and patients who need quicker, more reliable, and accurate results.
50 shades of brown
Pathologists love the flexibility in advanced staining. Still, it’s that exact same flexibility that is causing confusion. We aim to rid the advanced staining market of its blemishes, to rub away the variables and the subjectivity. Sakura provides standardised staining protocol for IHC and ISH to achieve optimal results. That’s achieved through offering automated start-to-end solutions with Advanced SMART Automation for tissue diagnostics to set a new standard – enabling pathologist professionals to achieve optimal results.
To discover more about how we approach advanced staining and how we’re changing the status quo, read more about our Optimal only approach.